In the quarter the firm acquired food and beverage testing firm Invisible Sentinel and partnered with Baxter International to develop acute kidney injury biomarkers.
The firm also reported full-year 2018 sales of €2.42 billion, a year-over-year increase of 6 percent on a reported basis, or 10 percent organically.
BioMérieux will adapt Invisible Sentinel's Veriflow DNA signature capturing technology on its Gene-Up system for food pathogen detection.
The BioFire FilmArray Pneumonia panel will be used to optimize clinical trial enrollment for an antibiotic to treat combat carbapenem-resistant A. baumannii infections.
Despite a recent positive economic modeling study, the debate over appropriate use of the ME panel seems likely to continue until more outcomes studies are conducted.
The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.
The BioFire FilmArray Pneumonia Panel was cleared by the FDA while the BioFire FilmArray Pneumonia Panel Plus was CE marked.
The company's third quarter revenue increase was driven in part by strong growth in its molecular biology clinical applications.
Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.
The firm attributed growth to a diversified geographic footprint and comprehensive offerings based on three key in vitro diagnostics technologies.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.